Park, Hyung
Yu, Chang
Pirofski, Liise-anne
Yoon, Hyunah
Wu, Danni
Li, Yi
Tarpey, Thaddeus
Petkova, Eva
Antman, Elliott M.
Troxel, Andrea B.
,
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1TR001445, UL1TR001445, UL1TR001445, UL1TR001445, UL1TR001445, UL1TR001445, UL1TR001445, UL1TR001445, UL1TR001445, UL1TR001445)
Article History
Received: 15 February 2024
Accepted: 18 June 2024
First Online: 26 June 2024
Declarations
:
: The trials enrolled hospitalized patients with a confirmed COVID-19 diagnosis via polymerase chain reaction or antigen test, not receiving mechanical ventilation, and randomized to receive CCP or control; all participants provided written informed consent. The NYU institutional review board (IRB) determined that this analysis was exempt because the data were deidentified. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki. The study is registered at Trial Registration PROSPERO: CRD42020213349. Members of the COMPILE collective Data and Safety Monitoring Board include Alison Bateman-House, PhD (NYU Grossman School of Medicine), Eric Boersma, PhD (Erasmus University Medical Center), David Glidden, PhD (University of California, San Francisco), L. Jeyaseelan, PhD (Christian Medical College), Emmanuel Lesaffre, PhD (KU Leuven), Grigorios Papageorgiou, PhD (Erasmus University Medical Center), Aitor Perez, PhD (Pivotal CR), Suman Pramanik, MD (Army Hospital Delhi), André Siqueira, MD (Instituo Nacional de Infectologica, Brasilia), John Szumowski, MD (University of California, San Francisco), Séverine Vermeire, MD (KU Leuven), and John Younger, MD (University City Science Center).
: The NYU institutional review board determined that this analysis was exempt because the data were deidentified. Trial Registration PROSPERO registration number CRD42020213349.
: The authors declare no competing interests.